Share Talk Ltd

Zak Mir talks to Dr Jim Millen, Non-Executive Chairman, Physiomics, regarding recent progress at the mathematical modelling, data science and biostatistics company, and issues regarding the forthcoming requisitioned meeting.What Physiomics actually doesPhysiomics is a specialised life sciences consultancy that works with companies developing new drugs. At its core, the business helps drug developers make better decisions about how they design and run studies.The company operates across two main areas. Mathematical modelling to support the design of preclinical and clinical trials, with a particular focus on oncology, though not limited to cancer treatment. Biostatistics, covering the statistical design of trials, reporting, planning, and regulatory interactions around trial outcomes. That combination matters. Drug development is expensive, time-consuming and high risk. The more rigorously a company can model likely outcomes and build trials correctly from a statistical standpoint, the better its chances o